GlaxoSmithKline: Venous Thrombosis trials

The registry lists 11 Venous Thrombosis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 2Phase 3 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hemorrhage Risk Prescribed ArixtraCompletedNCT01064362Results posted
• The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese PatientsCompletedNCT00981409Phase 3Results posted
• The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese PatientsCompletedNCT00911157Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing SurgeryCompletedNCT00843492Phase 3Results posted
• Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)CompletedNCT00443053Phase 3Results posted
• Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)CompletedNCT00320398Phase 3Results posted
• Odiparcil For The Prevention Of Venous ThromboembolismCompletedNCT00244725Phase 2Results posted
• ARIXTRA® Adherence in SVT Patients.CompletedNCT01691495
• Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related SurgeryCompletedNCT01444612
• Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate CancerCompletedNCT00312013Phase 3
• ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)CompletedNCT00041509Phase 2